|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||467.30 - 483.78|
|52-week range||439.65 - 673.62|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||27.97|
|Forward dividend & yield||3.94 (0.83%)|
|Ex-dividend date||09 May 2023|
|1y target est||N/A|
Key Insights Lonza Group's estimated fair value is CHF410 based on 2 Stage Free Cash Flow to Equity Lonza Group is...
Lonza Group AG ( VTX:LONN ) missed earnings with its latest half-year results, disappointing overly-optimistic...
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.